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Background: Extracellular Matrix (ECM) modifications have been reported in the Central 
Nervous System (CNS) of multiple sclerosis (MS) within post mortem brain tissue due to both 
the increased synthesis of ECM proteoglycans, and release activation of matrix 
metalloproteinase (MMPs). Multiple sclerosis (MS) is chronic inflammatory demyelinating 
disease written off as inflammation and demyelination disease, mainly located in central 
nervous system (CNS) white matter (WM). This study aims to clarify the potential 
pathophysiologic role of adisintegrin And metalloproteinase with thromboSpondin motif-9 
(ADAMTS-9) in MS. Materials and methods: Immunohistochemistry was performed to study 
the expression of ADAMTS-9 in both normal and MS white matter by confocal microscopic 
using specific antibodies. Fifty frozen blocks of brain tissue were obtained from the UK MS 
Society Tissue. All tissues blocks were marked by immunohistological material including 
antibodies to Human leukocyte antigen (HLA-DR) to assess the macrophage activation, Glial 
fibrillary acidic protein (GFAP) for astrocyte, neurofilaments (NF) for neurons and Von 
Willbrand factor (VWF) for endothelial. Results: In MS lesions, ADMTS-9 expression was 
increased in comparison to control samples. The expression of ADAMTS-9 was increased in 
active lesions as well as was associated with different cells from neuron, endothelial covering 
blood vessels astrocyte and microglia. Conclusion: The expression of ADAMTS-9 at the 
protein level was increased in active inflammatory lesions with evidence of myelin breakdown, 
suggesting that up-regulation of ADAMTS-9 may be a general phenomenon induced by CNS 
injuries. 
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Introduction 
The ADAMTS enzyme family contains 20 individual gene products (Apte, 2004). Certain 
members of this family (ADAMTS-1, -4, -5, -8, -9 and 15) can proteolytically process aggrecan 
within the interglobulin domain (IGD) separating its globular G1 and G2 domains at a specific 
Glu373-Ala374 bond or at one or more sites within the C-terminal glycosaminoglycan (GAG)-
bearing region  (Kuno et al., 2000; Tortorella et al., 1999). ADAMTS-9 was originally cloned 
by Clark et al., (2000) which localized the gene to chromosome 3p14.2-p14.3 (Clark et al., 
2000). Of all ADAMTSs, ADAMTS-9 comprises the highest number of C-terminal TSP-1 like 
domains (Gottschall & Howell, 2015). This is indicative of a protein with the ability to bind to 
heparan sulphate proteoglycans (HSPGs) of the blood brain barrier (BBB) basement membrane 
and glial scars as well as glycosphingolipid sulphatide, a lipid predominantly expressed in the 
brain (Zeng et al., 2006).    
ADAMTS-9 is widely expressed throughout the adult human body including brain, heart, 
placenta and others (Somerville et al., 2003). Levels of pro-inflammatory cytokines TNF and 
IL-1 are up-regulated in the CNS in MS (Di Penta et al., 2013) and ADAMTS-9 has been shown 
to be increased in response to these in chondrocytes and chondrosarcoma cells (Demircan et 
al., 2013; Yaykasli et al., 2009).Though, anti-inflammatory mediators such as TGFβ1 down-
regulated ADAMTS-9 expression in prostate cells (Cross et al., 2005). 
Unlike other ADAMTSs, such as ADAMTS-1 and ADAMTS-4, pro-domain cleavage of 
ADAMTS-9 leads to reduced versicanase activity rather than enhancing the catalytic function, 
and pro-domain processing occurs outside the cytoplasm on the cell surface (Kumar, Rao, & 
Ge, 2012). It has been suggested that ADAMTS-9 degradation of Chondroitin Sulphate 
Proteoglycans (CSPGs) may increase access of inflammatory cells to the CNS and lead to 
axonal damage. Alternatively, breakdown of CSPGs, by ADAMTS-9 may enable axonal 
regeneration and neurite outgrowth, which is inhibited by CSPGs (Tauchi et al., 2012). Several 
ADAMTSs have been shown to be elevated in human neurodegenerative disease and animal 
models of brain injury. ADAMTS-1, appears to be up-regulated in Down's syndrome, Pick's 
disease and Alzheimer's disease  (Miguel, Pollak, & Lubec, 2005) and ADAMTS-4 in MS 
(Haddock et al., 2006b). 
Enzymatic degradation of aggrecan and versican was observed in MS lesions, the aim of 
this study was to determine whether ADAMTS-9 is implicated in this ECM degradation; to 
develop an understanding of its activity by assessing its substrates ex vivo, which may then 
subsequently be exploited therapeutically through the design and application of molecules to 
increase or inhibit its activity. This study was designed to establish a reproducible protocol for 
both (1) the examination of ADAMTS-9 expression together with (2) phenotypic markers of 
specific CNS cells. 
Material and Methods  
1. Immunohistochemistry 
Serial cryostat sections of thirty MS active lesion (AL) and twenty normal brains were 
obtained from MS Tissue Bank in London under ethics number 08/MRE09/31. All specimens 
were cut and mounted onto polysine coated glass slides and fixed in ice-cold acetone for 10 
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mins. To determine the cellular origin of ADAMTS-9 expression, the dual-label 
immunofluorescence protocol was carried out, Briefly, sections were incubated with polyclonal 
ADAMTS-9 antibody overnight (1: 100) at -4°C and then detected by incubating with Alexa 
488 or Alexa 568-conjugated donkey anti-goat immunoglobulins (1: 1000, Invitrogen) at room 
temperature for 90 mins. Following three 5 min washes in PBS, sections were incubated in the 
mouse monoclonal antibodies to human GFAP (1: 1000), HLA-DR (1:50), NF-L (1:100) or 
vWF (1; 500) for 2 h. Sections were washed with PBS and incubated with secondary antibody 
488 or 568-conjugated rabbit anti-mouse.  
Human brain was removed from the deceased donor, specimens were prepared by cutting 
a whole brain into anterior and posterior halves by a single cut through the mammillary bodies. 
Each block was one centimetre thick coronal slices. Cutting slices were numbered according to 
their position, as anterior (frontal pole) or posterior (occipital pole) to the mammillary bodies. 
They were numbered A1, A2 etc and the latter were numbered P1, P2 etc respectively. The 
coronal slices were laid on a gride, cut into 2cm brain tissue blocks stored at -80°C. 
Furthermore, each patient already given an ID number related to the coronal section. For 
instance, MS027 A2D3, the patient number is 027, and A2 meaning coronal slice was taken 
from the second section anterior to the mammillary bodies, and the another brain tissue block 
derived from gride co-ordinate D3.  
MS cases include  seventeen females, mean ages 54.52 years (ranges 39-77) and thirteen 
males with a mean age of 60.54 years (range 38-75), while control cases include eight males, 
mean ages of 67.8 (range 35-88) and twelve females, mean age of 68.3 (range 50-77).Tissue 
blocks were stored at –80°C until required. All MS cases had a confirmed diagnosis of 
secondary progressive SPMS. 
Image Capture and Data Analysis   
Images of immunofluorescence on section to assess expression of ADAMTS-9 were taken by 
using confocal microscope. Immunofluorescence image to determine co-localization of ADAMTS-9 
were captured using a Zei 510 confocal scanning laser microscope equipment with krypton/ argon laser. 
Fluophores were excited at wavelengths of either 488 or 568 nm. Individual pixels were scanned for 
each channel with set intensity threshold, which were consistent for all analysis data. Co-localization 
pixels were represented as yellow in the composite image. Statistical analysis and any significance of 
any increase or decrease of ADAMTS-9 levels was determine via using image J software. All statistical 
analysis of data was performed via kruskal-wallis test, where, *p >0.01 and *p<0.001.  
Results  
ADAMTS-9 expression appeared to be associated with the cell body and the elongated 
processes of parenchymal astrocytes in active MS lesion. There were also increased levels of 
blood vessel associated ADAMTS-9 expression compared to normal appearing white matter 
(NAWM) and normal control (NC) white matter, which appeared to be both endothelial and 
astrocytic-end-feet in origin. To determine the exact cellular distribution of ADAMTS-9, dual 
label immunofluorescence was carried out with polyclonal goat anti-ADAMTS-9 antibody and 
rabbit anti-NF or mouse anti-HLA-DR or mouse anti-vWF or mouse anti-GFAP antibodies for 
identification of neurons, microglia/macrophages, endothelial cells and astrocytes respectively. 
Immunofluorescence was carried out following the application of three different commercially   
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available anti-GFAP antibodies to determine the cellular location of ADAMTS-9 protein 
expression within astrocytes cells, and to ensure there were no cross reactions (anti-GFAP, 
Abcam, UK; anti-GFAP, Millipore, UK; anti-GFAP, Invitrogen, UK). Following initial 
optimisation, mouse anti-GFAP antibody from Millipore was carried forward for use in this 
experiment.  
Utilisation of the Zeiss 510 software enabled individual pixels to be scanned and viewed 
as a yellow colour if true co-localization existed between the two channels of interest. Co-
localisation was observed with ADAMTS-9 and cerebral vascular endothelium in the lesion 
(Figure 1). Co-localisation was also observed in the foamy macrophages and activated 
microglia in MS active lesion (Figure 2). Co-localisation of the Neuron phenotypic marker (NF) 
with ADAMTS-9 provided definitive evidence of ADAMTS-9 expression by astrocyte cells 
within MS active lesions as shown in figure 3. In addition, expression of ADAMTS 9 was 
associated with astrocyte cells confirmed with GFAP proteins as showed figure 4. All these 
results were compared using image J software analysis and showed that much greater 
expression of ADAMTS-9 was observed in active lesion compared to NC and MS NAWM as 
shown in figure 5.  
 
 
Figure 1: Dual label immunofluorescence of ADAMTS-9 and vWF in MS AL brain tissue sections: Dual label 
immunofluorescence for (a) vWF (green) and (b) ADAMTS-9 (red) in MS active lesion white matter (MS062 P1C3) with high 
levels of parenchymal ADAMTS-9 immunoreactivity. (C) Co-localisation is represented by the pixels in quadrant 3 on the 
graph and is demonstrated as yellow pixels in the composite image (d) following Zeiss 510 CSLM software reading of individual 
pixels for each fluorophore. V= vessel. 
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Figure 2: Dual label immunofluorescence of ADAMTS-9 and HLA-DR in MS AL brain tissue: Dual label immunofluorescence 
for (a) HLA-DR (green) and (b) ADAMTS-9 (red) in MS active lesion white matter (MS062 P1C3) with high levels of 
parenchymal ADAMTS-9 immunoreactivity. (c) Co-localization is represented by the pixels in quadrant 3 on the graph and is 
demonstrated as yellow pixels in the composite image (d) following Zeiss 510 CSLM software reading of individual pixels for 
each fluorphore. 
 
Figure 3: Dual label immunofluorescence of ADAMTS-9 and NF in MS AL brain tissue: Dual label immunofluorescence for 
(a) NF (green) and (b) ADAMTS-9 (red) in MS active lesion white matter (MS062 P1C3) with high levels of parenchymal 
ADAMTS-9 immunoreactivity. (c) Co-localization is represented by the pixels in quadrant 3 on the graph and is demonstrated 
as yellow pixels in the composite image (d) following Zeiss 510 CSLM software reading of individual pixels for each fluorphore. 
Arrows indicate co-localisation of ADAMTS-9 and NF on a few axons. V= vessel. 
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Figure 4:  Dual label immunofluorescence of ADAMTS-9 and GFAP in MS AL brain tissue: Dual label immunofluorescence 
for (a) GFAP (red) and (b) ADAMTS-9 (green) in MS active lesion white matter (MS062 P1C3) with high levels of parenchymal 
ADAMTS-9 immunoreactivity. (C) Co-localization is represented by the pixels in quadrant 3 on the graph and is demonstrated 
as yellow pixels in the composite image (d) following Zeiss 510 CSLM software reading of individual pixels for each fluorphore. 
V= vessel. 
 
Figure 5: Comparison of expression of ADAMTS-9 in MS and NAWM brain tissue by IHC. Image J software analysis shows 
expression of ADAMTS-9 normal control and active lesion. Low level of HLA-DR were observed in areas of intact myelin 
and no level recorded of ADAMTS-9. In contrast, high level of ADAMTS-9 in going demyelination along with activated 
microglia. Data represented as mean using kruskal-wallis, n=50 five reading for each region.  
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Discussion 
The results presented here validate the spectrum of ADAMTS-9 distribution in CNS 
tissue of MS by IHC, along with confocal microscope analysis of the relative level of 
ADAMTS-9 expression in normal control white matter, NAWM and the active lesions. Tissue 
was classified based on evidence of recent myelin breakdown and extent of cellular activation 
as determined by oil red O (ORO) staining and HLA-DR immunoreactivity, classification 
parameters as described by other authors  (Sanders, Conrad, & Tourtellotte, 1993; Van der Valk 
& De Groot, 2000). The first objective of this study was to determine whether ADAMTS-9 was 
expressed and then to establish a reproducible protocol for identification of ADAMTS-9 by 
immunofluorescence in snap frozen human autopsy brain material.  
High levels of ADAMTS-9 were presented in regions of demyelination, which has not 
previously been reported in MS by IHC.  In contrast, much lower levels of ADAMTS-9 was 
consistently found in normal appearing white matter (NAWM) of MS and normal control 
samples tissue where there was no evidence of demyelination. Previous educations using qRT-
PCR shown that ADAMTS-9 was expressed by differentiated neuroblastoma cells lines and 
significantly up-regulated following transient middle cerebral artery occlusion (tMCAo) in the 
rat (Reid et al., 2009). The ADAMTS-9 expression was associated with the endothelium of 
blood vessels and with the cell body and elongated processes of parenchymal astrocytes and 
the astrocytic end feet that encompass the cerebral vasculature. Co-localisation of ADAMTS-9 
with the astrocyte phenotypic marker, GFAP, or the endothelial marker, vWF or neuronal 
marker, NF-L following dual labelled immunohistochemistry, confirmed the morphological 
observations and clearly demonstrated that these three cell types are responsible for ADAMTS-
9 expression. These observations confirm ADAMTS-9 expression within MS active lesions 
similar to that for other matrix metalloproteinase informed previously e.g. ADAMTS-4 and 
ADAM 17 (Goddard, Bunning, & Woodroofe, 2001; Haddock et al., 2006b). ADAMTS-9 was 
also established to be expressed by activated macrophages/microglia cells in MS tissue and was 
up-regulated in MS. principally in active lesions where ADAMTS-9 immunreactivity is evident 
in numerous large foamy macrophages, implicating a possible role in MS pathology.  
Changes in ADAMTS-9 reported in human chondrocytes in rheumatoid arthritis (RA) 
results from transcriptional changes in ADAMTS-9 or changes in protein activity due to up-
regulation of aggrecan within injury sites (Demircan et al., 2005). ADAMTS-9 may be involved 
in the loss of ECM by cleaving proteoglycans, as demonstrated for other ADAMTSs and other 
tissues (Lemarchant et al., 2013; Sandy et al., 2001) and as described here. Sobel and Ahmed, 
(2001) demonstrated that in active plaque centre and active lesions, CSPGs were decreased in 
the ECM and accumulated in foamy macrophage which is similar to our findings in a previous 
paper. This loss of CSPGs is related to the high levels of ADAMTS-9 observed in active MS 
plaques (Sobel & Ahmed, 2001). 
Transcriptional induction of ADAMTSs e.g. ADAMTS-1 and 9 in neurons and astrocytes 
following physical or toxic injury in the CNS has been reported and it was suggested that this 
expression at the site of injury may favour neurite outgrowth (Cua et al., 2013; Lemons, Sandy, 
Anderson, & Howland, 2001). It has been reported that ADAMTS-4 cleaves versican in vivo,  
in a manner similar to the ADAMTS-mediated cleavage of aggrecan and versican in cartilage 
(Demircan et al., 2005; Tortorella, Malfait, Deccico, & Arner, 2001), spinal cord (Lemons et 
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al., 2001; Rodrıguez-Manzaneque et al., 2002) and brain tissue (Matthews et al., 2000; Westling 
et al., 2004). It was also reported that ADAMTS-4 was abundant in MS active lesions (Haddock 
et al., 2006b), in agreement with our reported observations for ADAMTS-9. Thus, ADAMTS-
9 together with ADAMTS-4 expression in the CNS, may contribute to remodelling of the ECM 
in the brain in MS patients.  On the other hand, others also suggest that the level of endogenous 
ADAMTSs is not sufficient to recover plasticity and functional recovery after human brain 
injury. The cleavage of CSPGs induced by glial cells may be achieved not only by ADAMTS-
9 but also by other ADAMTSs and MMPs, which are also up-regulated after neuronal injuries 
(Nakamura et al., 2000; Tauchi et al., 2012). MMPs also cleave other matrix proteins, such as 
laminin and collagen, leading to loss of blood brain barrier integrity; enhancing the infiltration 
of immune cells which may worsen the pathology of MS (Rosenberg, Estrada, & Dencoff, 
1998). 
ADAMTS-9 may play a role in a number of ways in the development of MS; proteolytic 
cleavages of ECM Heparan sulphate proteoglycan (HSPGs) of the BBB basement membrane 
and glial scar as well as cleavage of HGSPs into their soluble form, may create a chemotatic 
gradient for inflammatory cells to enter the CNS (Chen, Herndon, & Lawler, 2000; Zeng et al., 
2006). ADAMTSs are reported to cleave CSPGs and adhesion molecules from the luminal 
surface of blood vessels; however in MS, increased expression of CSPGs has been reported, 
suggesting an imbalance in enzyme/inhibitor activity. ADAMTS-9 expression has been 
demonstrated to be associated with astrocytes and activated macrophages/microglia and 
expressed at high levels in lesions with high level of cellular activity as gauged by HLA-DR 
and ORO expression. ADAMTS-9 cleaves CSPGs thereby possibly subjecting neurons to its 
cytotoxic effects (Hoffmann et al., 2015). CSPGs have been reported to inhibit myelin repair 
(Lau, Cua, Keough, Haylock-Jacobs, & Yong, 2013) neurite outgrowth (Barritt et al., 2006) 
and axon regeneration (Brown et al., 2012; Shen et al., 2009). 
Following up-regulation, ADAMTS-9 could be contributing to neuronal regeneration by 
two potential mechanisms; 1) promotion of neuronal differentiation/proliferation by enzymatic 
activity in the nucleus (Somerville et al., 2003) or 2) operating as a peptidase on the cell surface 
of migrating CNS cells and clearing a path through the ECM or glial scar by degradation of 
CSPGs (Somerville et al., 2003), enabling migration of oligodendrocyte precursor cells. 
Alternatively, the breakdown of CSPGs by ADAMTS-9 could have a damaging effect on the 
CNS by allowing the migration of inflammatory cells and activated macrophages to susceptible 
neurons. The efficiency by which ADAMTSs cleaves CSPGs does not appear to be as high as 
MMPs, perhaps limiting the impact of the peptidase as proteoglycanase in vivo (Somerville et 
al., 2003).Therefore the up-regulation of ADAMTS-9 expression following stroke is not 
necessarily a bad thing because it is unlikely that the normal ECM structure will be significantly 
degrade by the peptidase.  
The identification of the cells responsible for the synthesis of ADAMTS-9 is important 
when analysing the functional aspects of ADAMTS-9. ADAMTS-9 could be the sheddase 
responsible not only for CSPGs breakdown, but also for release of growth factors and adhesion 
molecules (Luan et al., 2008). Moreover, astrocytes and macrophages can contribute to immune 
regulation through their role in resealing of the BBB and their direct effects on immune cell 
modulation molecules, such as TGFβ, and TNF and proteoglycans (Faulkner et al., 2004; Rolls 
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et al., 2006). Proteoglycan, and principally CSPGs, are known for their immune-related activity 
in peripheral tissue. Owing to their adhesiveness to chemo-attractive agents and growth factors 
that are required for recruiting and activating immune cells, proteoglycans can capture these 
factors increasing their focal concentration and thereby targeting the immune response to the 
injured areas (Nandini & Sugahara, 2006; Rolls et al., 2006). 
Reid et al., (2009) provided evidence that IL-1β and TNF-α potentially up-regulated 
ADAMTS-9 in an astrocytic cell line (U373-MG) by activating transcription factor NFkB. This 
study provided strong evidence that ADAMTS-9 expression is modulated by pathological 
conditions that occurs in response to CNS injury (Reid et al., 2009). The ADAMTS-9 data 
described here are consistent with previous studies of ADAMTS-1 and -4 expressions, which 
were both up-regulated in MS. In contrast to ADAMTS-5 and -8, levels which were not 
significantly raised in response to experimental stroke or in MS (Chen et al., 2000; Haddock et 
al., 2006a; Tian et al., 2007). However, Luan et al., (2008) indicated that specific blocking 
antibodies against IL-1β and TNF-α dramatically inhibited ADAMTS-7 and ADAMTS-12 
induction in chondrocytes in vitro, and the suppression of TNF-α and IL-1β expression by 
siRNA in human chondrocytes prevented ADAMTS-7 and ADAMTS-12mediated degradation 
of cartilage oligomeric matrix protein. Regardless of cell source, ADAMTS-9 expression by 
astrocytes and macrophages/microglia would allow cleavage of CSPGs, resulting in promotion 
of pro-inflammatory after acute CNS injury. These suggestions are in agreement with other 
reports indicating that, in the periphery, CSPGs regulate the motility and activation of 
macrophages (Hayashi, Kadomatsu, & Muramatsu, 2001; Rolls et al., 2006), dendritic cells 




All previous studies have been reported that CSPGs, including aggrecan was up regulated in MS 
lesions, these increasing were associated with breakdown of ECM proteins including CSPGs. Here we 
report the cellular origin and distribution of ADAMTS-9 expression within clinically and 
neuropathologically confirmed MS and normal control white matter, assessed by IHC and confocal 
microscope. ADAMTS-9 expression was associated predominantly with activated 
macrophages/microglia, parenchymal astrocytes and to lesser extent with blood vessel endothelium and 
axons in MS white matter. We demonstrated here that ADAMTS-9 expression at the protein level was 
also increased in active inflammatory lesions with evidence of myelin breakdown, suggesting that up-
regulation of ADAMTS-9 may be a general phenomenon induced by CNS injuries. ADAMTS-9 could 
degrade aggrecan and versican and reverse the neurite outgrowth inhibition mediated by human brain 
proteoglycans allowing OPCs to cross the glial scar to repair axons. However, as repair in MS is limited; 
this degradation of ECM proteins deposited in lesions does not allow the repair process to be complete. 
Further studies on this enzyme are now required to define its function in normal CNS physiology and in 
the pathological process of MS. 
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 الوفاة بعد الدماغ نسيج في ADAMTS-9 زيمنل  الجيني التعبير تقدير 
 4أشلي ادوارد رو سوسى ،3وودروفنيكوال ، 2إسماعيل معمر مخزوم الحويج، 1السعداوي أبوعنيزة
  ليبيا –جامعة المرقب  –كلية التقنية الطبية  –قسم المختبرات الطبية  2 ،1
 بريطانيا -كلية لندن العظمى  –قسم علم االعصاب 3
  ماليزيا –جامعة ساراواك الماليزية  –كلية الطب والعلوم الصحية  –قسم الطب الالسريري 4
 ملخص البحث
الخارج خلوية في الجهاز العصبي المركزي لمرض التصلب المتعدد في الدماغ ظهرت الدرسات السابقة ان المادة ا
مابعد الوفاة تتعرض الي تعديالت ناجمة عن زيادة في تصنيع البروتينات السكرية للمادة الخارج خلوية و طرح 
عنه ازالة  التصلب المتعدد هو عبارة عن مرض التهابي مزمن ينتج . (MMPsوتنشيط انزيمات المادة المعدنية )
اليضاح الدور  المناعي النسيج تقنية استخدام تمالمالنين في المادة البيضاء للجهاز العبي المركزي. في هذه الدراسة 
 المادة نسيج في االنزيم لهذا الجيني التعبير لمعرفة المتعدد التصلب مرض في ADAMTS-9الفسيولوجي النزيم  
 متخصصة.اجريت مضادة اجسام باستخدام وذلك البؤري المجهر بواسطة تعددالم بالتصلب المصاب و الطبيعي البيضاء
 تم االنسجة هذه كل المتعدد. التصلب النسجة البريطانية المؤسسة من المخ نسيج من عينة 50 على الدراسة هذه
 بروتين و الكبيرة البالعم نشاط لتقدير (D2-HLA) البيضاء الدم كريات مستضد من لكل مضادة بأجسام تخصيصها
GFAP وعامل للعصبونات العصبية والخيوط النجمية للخاليا VWF هذه اظهرت الدموية. لالوعية المبطنة للخاليا 
 للدماغ. الطبيعي بالنسيج مقارنة المتعدد التصلب انسجة في ADAMTS-9 النزيم الجيني التعبير في ارتفاع الدراسة
 والخاليا الدموية لالوعية المبطنة الخاليا و كالعصبونات مختلفة ياخال بعدة مرتبط الجيني التعبير في االرتفاع هذا
 ان الى يشير النشطة االلتهابية البقع في ADAMTS-9 انزيم الجيني التعبير ارتفاع ان الدقيقة. العبية والخاليا النجمية
  المركزي. العصبي الجهاز اصابات عند شائعة ظاهرة يكون قد االرتفاع هذا
 الدماغ ،ADAMTS-9 ،التصلب المتعدد المفتاحية:الكلمات 
 
